home / stock / nvsef / nvsef quote
Last: | $96 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $96 |
High: | $0 |
Low: | $0 |
Volume: | 50 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$96 | $0 | $96 | $0 | $0 | 50 | 04-26-2024 |
$96 | $0 | $96 | $0 | $0 | 16 | 04-25-2024 |
$96 | $96.72 | $96 | $96.74 | $95.36 | 51,948 | 04-23-2024 |
$95.11 | $95.27 | $95.11 | $95.27 | $95.11 | 492 | 04-22-2024 |
$90.24 | $0 | $90.24 | $0 | $0 | 2 | 04-19-2024 |
$90.24 | $90.24 | $90.24 | $90.24 | $90.24 | 10,985 | 04-18-2024 |
$93.6375 | $0 | $93.6375 | $0 | $0 | 97 | 04-17-2024 |
$93.6375 | $0 | $93.6375 | $0 | $0 | 10,592 | 04-16-2024 |
$93.6375 | $0 | $93.6375 | $0 | $0 | 133 | 04-15-2024 |
$93.6375 | $0 | $93.6375 | $0 | $0 | 46 | 04-12-2024 |
$93.6375 | $93.8 | $93.6375 | $94.25 | $93.6375 | 82,320 | 04-11-2024 |
$94.1 | $94.1 | $94.1 | $94.1 | $94.1 | 504 | 04-10-2024 |
$95.7 | $95.7 | $95.7 | $95.7 | $95.7 | 1,698 | 04-09-2024 |
$94.91 | $0 | $94.91 | $0 | $0 | 20 | 04-05-2024 |
$94.91 | $94.82 | $94.91 | $97.11 | $94.82 | 5,408 | 04-04-2024 |
$92.44 | $92.28 | $92.44 | $92.44 | $92.28 | 400 | 04-03-2024 |
$95 | $95 | $95 | $95 | $95 | 6,373 | 04-02-2024 |
$96.51 | $0 | $96.51 | $0 | $0 | 56 | 04-01-2024 |
$96.51 | $96.39 | $96.51 | $96.51 | $96.39 | 320 | 03-29-2024 |
$96.51 | $96.39 | $96.51 | $96.51 | $96.39 | 320 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...